Phases of Aβ-deposition in the human brain and its relevance for the development of AD

By D. Thal, Udo Rüb, M. Orantes, H. Braak. Neurology, 2002

3,277 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/3d348ed6a07e2d1a724ad41d80272b9b524d292a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Nora D. Volkow
2. Gene-Jack Wang
3. Helene Benveniste
4. E. Masliah
5. C. Duyckaerts
6. Arthur W. Toga
7. L. Beckett
8. Lary C. Walker

In Physiology

1. Dennis W. Dickson
2. Clifford R. Jack Jr.
3. William E. Klunk
4. Thomas Wisniewski
5. Brittany N. Dugger
6. Eleanor Drummond
7. Helene Benveniste
8. John Q. Trojanowski

In Psychiatry and Mental health

1. Dennis W. Dickson
2. Clifford R. Jack Jr.
3. Nora D. Volkow
4. John Q. Trojanowski
5. John Hardy
6. Eleanor Drummond
7. Thomas Wisniewski
8. Brittany N. Dugger

Citations in the corpus

• Pathogenic Protein Seeding in Alzheimer’s Disease and Other Neurodegenerative Disorders (2011, methodology): “Crosssectional autopsy studies indicate that b-amyloid (Ab) plaques (A) first appear in the neocortex, followed by the allocortex and finally subcortical regions.(21) In the brain, neurofibrillary tangles (B) occur first in the locus coeruleus and transentorhinal area and then spread to the amygdala”
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B (2004, background): “This pattern is very consistent with that described in postmortem studies of amyloid deposition in AD brain.(25,26) PIB images from HC subjects showed little or no PIB retention in cortical areas, leaving the subcortical white matter regions highest in relative terms.”
• Alzheimer's disease (2018, methodology): “Different staging systems for Ab include those from Braak and Braak [16], the Thal criteria [17] and the Consortium to Establish a Registry for Alzheimer Disease (CERAD) [18].”
• National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease (2012, methodology): “identified by immunohistochemistry [38] and those reported by Thal et al, who propose categorization based on progressive Ab deposition in medial temporal lobe structures [24] or on phases of Ab distribution across multiple areas of brain [23].”
• Pathology of Neurodegenerative Diseases. (2017, background): “Staging schemes have been developed for Alzheimer’s disease (AD) (Braak and Braak 1991; Thal et al. 2002), Parkinson’s disease (PD) (Braak et al.”
• Classification and basic pathology of Alzheimer disease (2009, background): “the topography of the amyloid deposits [318].”
• The Alzheimer’s Disease Neuroimaging Initiative: Progress report and future plans (2010, background): “[7] Thal DR, Rub U, Orantes M, Braak H.”